Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Novartis ( NYSE:NVS ) is leaning further into immunology, agreeing to acquire biotech firm Excellergy Inc. for up to $2 billion as it looks to reinforce its pipeline in food allergies and related conditions. The transaction includes upfront and milestone-based payments, though the company did not provide a detailed breakdown. Shares were little changed in early trading in Zurich after gaining 9% year to date. Excellergy's lead candidate remains in early-stage testing and targets the Immunoglobulin E antibody linked to asthma, eczema, and other allergic diseases, with Novartis indicating the therapy could potentially expand symptom control across food allergies, hives, and related conditions. Warning! GuruFocus has detected 2 Warning Sign with CRWD. Is NVS fairly valued? Test your thesis with our free DCF calculator. The move extends a broader stretch of deal activity as Novartis navigates pressure from generic competition on several of its aging blockbusters. The company warned
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE-IgAN Study [Yahoo! Finance]Yahoo! Finance
- AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [Yahoo! Finance]Yahoo! Finance
- The Vanguard ETF Up About 28% in the Past Year That Almost Nobody Outside of Income Investors Knows [Yahoo! Finance]Yahoo! Finance
- AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [TheStreet.com]TheStreet.com
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website